The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Initial experience with erlotinib in advanced non-small cell lung cancer in the Kingdom of Saudi Arabia.
A. A. M. Alolayan
No relevant relationships to disclose
S. Musaad
No relevant relationships to disclose
H. Bamefleh
No relevant relationships to disclose
M. Nounou
No relevant relationships to disclose
A. R. Jazieh
No relevant relationships to disclose